Niraparib Oral Product

DRUG2 trials

Sponsors

University Hospital Southampton NHS Foundation Trust, Institut Paoli-Calmettes

Conditions

Breast CancerMesothelioma, Malignant

Phase 1

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

Not yet recruitingNCT05519670

Institut Paoli-CalmettesBreast Cancer

Start: 2023-03-31End: 2027-12-31Target: 72Updated: 2022-08-29

Phase 2

Niraparib Efficacy in Patient With Unresectable Mesothelioma

CompletedNCT05455424

University Hospital Southampton NHS Foundation TrustMesothelioma, Malignant

Start: 2022-07-11End: 2025-01-31Updated: 2025-05-15

Related Papers

Abstract CT263: Efficacy and multiomic analysis of Niraparib in relapsed mesothelioma: NERO a randomized phase II trial

Cancer Research2025-04-251 citations

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

2024-08-2119 citations

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

BMJ Open2023-11-014 citations

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.

Journal of Clinical Oncology2023-06-011 citations